Imovax Polio (Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po)

The vaccine contains chemically inactivated poliovirus particles that cannot cause disease. When injected, these antigens are recognized by the immune system, prompting B‑cells to produce neutralizing antibodies specific to each poliovirus serotype. The resulting immune memory provides long‑term protection against future exposure.

The dosage and schedule of Imovax Polio are determined by the prescribing healthcare professional based on age, vaccination history, and local immunization guidelines. The prescriber decides the volume, route (intramuscular or subcutaneous), and timing of each dose.

Safety data for Imovax Polio in pregnancy are limited. Healthcare providers should weigh the benefits of immunization against potential risks. The vaccine is not known to be excreted in breast milk, but a clinician’s assessment is recommended before administration to pregnant or nursing individuals.

To place an order, submit an enquiry on the Imovax Polio product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Imovax Polio is an inactivated (killed) vaccine, whereas some alternatives, such as oral polio vaccine (OPV), use live attenuated virus. Inactivated vaccines cannot cause vaccine‑derived poliovirus infection and are preferred in settings where OPV risks are a concern. Both provide protection, but the choice depends on public‑health strategy and patient factors.

Imovax Polio must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport and storage preserves vaccine potency.

The vaccine is supplied as an injectable solution and is given either intramuscularly or subcutaneously by a qualified healthcare professional. The injection site is typically the deltoid muscle for adults or the anterolateral thigh for infants, following standard aseptic techniques.

Serious but rare adverse events include anaphylactic allergic reactions, Guillain‑Barré syndrome, and neurologic complications such as seizures or encephalitis. Immediate medical attention is required if signs of a severe allergic reaction (e.g., difficulty breathing, swelling of the face) occur after vaccination.

Individuals with a known severe allergy to any component of the vaccine, including the inactivated poliovirus antigens, should not receive Imovax Polio. Persons who have experienced a serious adverse reaction to a previous dose of this vaccine should also avoid further administration.